GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VioQuest Pharmaceuticals Inc (OTCPK:VOQP) » Definitions » Gross Margin %

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Gross Margin % : 0.00% (As of Jun. 2008)


View and export this data going back to . Start your Free Trial

What is VioQuest Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. VioQuest Pharmaceuticals's Gross Profit for the three months ended in Jun. 2008 was $0.00 Mil. VioQuest Pharmaceuticals's Revenue for the three months ended in Jun. 2008 was $0.00 Mil. Therefore, VioQuest Pharmaceuticals's Gross Margin % for the quarter that ended in Jun. 2008 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for VioQuest Pharmaceuticals's Gross Margin % or its related term are showing as below:


VOQP's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.91
* Ranked among companies with meaningful Gross Margin % only.

VioQuest Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Jun. 2008 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for VioQuest Pharmaceuticals was 0.00% per year.


VioQuest Pharmaceuticals Gross Margin % Historical Data

The historical data trend for VioQuest Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VioQuest Pharmaceuticals Gross Margin % Chart

VioQuest Pharmaceuticals Annual Data
Trend Dec98 Dec99 Dec00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70.70 43.57 36.19 - -

VioQuest Pharmaceuticals Quarterly Data
Sep03 Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of VioQuest Pharmaceuticals's Gross Margin %

For the Biotechnology subindustry, VioQuest Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VioQuest Pharmaceuticals's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VioQuest Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where VioQuest Pharmaceuticals's Gross Margin % falls into.



VioQuest Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

VioQuest Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2007 is calculated as

Gross Margin % (A: Dec. 2007 )=Gross Profit (A: Dec. 2007 ) / Revenue (A: Dec. 2007 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

VioQuest Pharmaceuticals's Gross Margin for the quarter that ended in Jun. 2008 is calculated as


Gross Margin % (Q: Jun. 2008 )=Gross Profit (Q: Jun. 2008 ) / Revenue (Q: Jun. 2008 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


VioQuest Pharmaceuticals  (OTCPK:VOQP) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

VioQuest Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Jun. 2008 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


VioQuest Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of VioQuest Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 2287, Minneapolis, MN, USA, 55402
Website
VioQuest Pharmaceuticals Inc is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment.
Executives
Mark D Dacko director, officer: CFO and Secretary 800 NICOLLET MALL SUITE 2690, MINNEAPOLIS MN 55402
Christopher P. Schnittker officer: V.P. & Chief Financial Officer 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Brian Lenz officer: CFO and Treasurer 65 COMMERCE WAY, HACKENSACK NJ 07601
Lau Johnson Yiu Nam director
Michael Weiser director C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133
Stephen Rocamboli director, officer: Secretary C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Daniel E Greenleaf director, officer: President and CEO C/O NABI BIO PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD., N.W., BOCA RATON FL 33487
Lester E Lipschutz 10 percent owner WOLF BLOCK SCHORR AND SOLIS COHEN, 1650 ARCH STREET, PHILADELPHIA PA 19103
David M Tanen director TWO RIVER GROUP HOLDINGS, LLC., 689 FIFTH AVENUE, NEW YORK NY 10022

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Headlines

No Headlines